ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,915.24
-0.93%
Dow Jones
42,628.83
-0.85%
US Dollar vs MXN
20.504
0.89%
Brent Oil
74.165
0.73%
Bitcoin
91,859.72
-1.78%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Silence Therapeutics PLC (SLN)

  7. Silence Therapeutics PLC (SLN) Noticias

SLN

Silence Therapeutics (SLN)

Silence Therapeutics PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SLN
FechaHoraFuenteTítuloSímboloCompañía
09/12/202407:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
09/12/202406:30Business WireSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
26/11/202407:00Business WireSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
18/11/202413:30Business WireSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingNASDAQ:SLNSilence Therapeutics PLC
14/11/202412:13Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SLNSilence Therapeutics PLC
14/11/202407:00Business WireSilence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/11/202407:00Business WireSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
27/08/202407:00Business WireSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
15/08/202406:30Business WireSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
27/06/202406:30Business WireSilence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera PatientsNASDAQ:SLNSilence Therapeutics PLC
24/06/202407:30Business WireSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
20/06/202406:30Business WireSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
30/05/202407:30Business WireSilence Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
16/05/202407:30Business WireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressNASDAQ:SLNSilence Therapeutics PLC
14/05/202415:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLNSilence Therapeutics PLC
08/05/202416:14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
30/04/202407:30Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
29/04/202407:30Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
08/04/202410:48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
13/03/202406:05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/03/202406:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
13/03/202406:00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
28/02/202407:00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024NASDAQ:SLNSilence Therapeutics PLC
23/02/202407:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialNASDAQ:SLNSilence Therapeutics PLC
14/02/202408:54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
05/02/202407:00Business WireSilence Therapeutics Announces Oversubscribed $120 Million Private PlacementNASDAQ:SLNSilence Therapeutics PLC
31/01/202406:00Business WireSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SLNSilence Therapeutics PLC
01/12/202306:00Business WireSilence Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:SLNSilence Therapeutics PLC
14/11/202306:00Business WireSilence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:SLNSilence Therapeutics PLC
08/11/202306:00Business WireSilence Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:SLN

Su Consulta Reciente

BIT
NSCIT1958650
Intesa Sanpaolo
NASDAQ
SPWR
SunPower
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados